Welcome to our dedicated page for Biohaven news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven stock.
Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company pioneering innovative therapies in immunology, neuroscience, and oncology. This page provides real-time access to official press releases, financial disclosures, and progress updates on Biohaven’s cutting-edge platforms like the MoDE protein degradation technology and TRAP degraders.
Investors and industry professionals will find curated updates on clinical trial milestones, regulatory submissions, and strategic partnerships. Key content includes earnings reports, FDA communications, and advancements in autoimmune disease treatments, neurological disorder therapies, and oncology programs.
Bookmark this page for direct access to Biohaven’s verified announcements, ensuring you stay informed about developments impacting the company’s scientific and financial trajectory. Regular updates provide critical insights for evaluating Biohaven’s position in competitive therapeutic markets.
Biohaven Pharmaceuticals (NYSE:BHVN) has partnered with Rick Ware Racing for the 2021 NASCAR Cup Series, featuring Nurtec™ ODT as the primary sponsor for the No. 51 car. Approved by the FDA in February 2020 for acute migraine treatment, Nurtec ODT is the first orally disintegrating tablet in its category. This partnership aims to raise awareness about migraine relief among the nearly 40 million individuals affected in the U.S. The team will also participate in the Military Salutes Program, visiting 50 military bases to support troops who may suffer from migraines.
Biohaven Pharmaceutical (NYSE: BHVN) recently announced a value-based contract with Prime Therapeutics for its migraine treatment, NURTEC ODT (rimegepant), addressing the needs of the 55% of migraine patients who find current treatments inadequate. The contract aims to protect health plans financially from high usage while ensuring that the medication's price aligns with its value. NURTEC ODT, FDA-approved in February 2020, offers quick relief, with effects felt within an hour, catering to a significant unmet need among nearly 40 million U.S. migraine sufferers.
Biohaven Pharmaceutical (BHVN) has announced a new investigator-led clinical trial for a CGRP-receptor antagonist aimed at treating plaque psoriasis, led by Dr. Richard Granstein from Weill Cornell Medicine. This study will measure disease severity and quality of life after 16 weeks of treatment compared to placebo. The trial highlights Biohaven's commitment to exploring CGRP's role in dermatological conditions, enhancing their neuroinnovation portfolio, which includes FDA-approved Nurtec for migraines. The trial's commencement signifies potential expansion into dermatological therapies.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced its partnership with the National Ataxia Foundation (NAF) on November 11, 2020, becoming the first industry member to support the NAF Drug Development Collaborative. This initiative aims to enhance the development of treatments for Ataxia, a group of neurodegenerative diseases without current FDA-approved therapies. Biohaven is actively enrolling participants in a Phase 3 clinical trial for its drug, troriluzole, targeting Spinocerebellar Ataxia.
Biohaven Pharmaceutical Holding Company (NYSE: BHVN) reported third-quarter 2020 financial results, highlighting net revenues of $17.7 million for NURTEC ODT, significantly surpassing expectations amid pandemic challenges. The drug has garnered over 220,000 prescriptions in just six months, indicating strong market uptake. The company anticipates NURTEC's annual US market potential to reach $4B to $5B. Recent milestones include FDA acceptance of an sNDA for NURTEC's preventive use, and $60 million raised for BioShin to expand their clinical portfolio in the Asia-Pacific region.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will report its third quarter 2020 financial results on November 9, 2020, at 8:30 a.m. ET. The earnings call will cover results for the quarter ending September 30, 2020, alongside recent accomplishments and future milestones. Participants can join via telephone or the company's website. Biohaven specializes in innovative therapies for neurological and neuropsychiatric diseases, including the FDA-approved NURTEC™ ODT for migraine treatment, with a pipeline targeting various crucial disorders.
Biohaven Pharmaceutical Holding Company (NYSE: BHVN) announced that the FDA has accepted its supplemental New Drug Application (sNDA) for NURTEC™ ODT (rimegepant) for migraine prevention. The PDUFA goal date for the FDA's review is set for 2Q2021. NURTEC ODT, launched in March 2020, is the first orally disintegrating tablet approved for acute migraine treatment and potentially addresses both acute and preventive needs. Clinical trials indicate a significant reduction in monthly migraine days for patients using rimegepant. The drug is expected to offer a convenient alternative to injectable therapies.
Biohaven Pharmaceutical (NYSE: BHVN) announced a successful $60M Series A funding for its Asia-Pacific subsidiary, BioShin Limited. The investment, led by OrbiMed, aims to advance Biohaven's clinical portfolio, including the upcoming Phase 3 study of NURTEC™ ODT for migraine treatment in China and Korea. BioShin also plans to enroll sites for a global trial of troriluzole in Spinocerebellar Ataxia. The funding allows BioShin to operate independently without relying on Biohaven's financial support. Biohaven retains majority ownership of BioShin.
Biohaven Pharmaceutical (BHVN) announced FDA authorization to initiate clinical trials for oral zavegepant (BHV-3500) and achieved first-in-human dosing in a Phase 1 trial. The company secured up to $250 million in funding to advance its CGRP receptor antagonist program, which includes both intranasal and oral formulations for migraine and non-migraine indications. Intranasal zavegepant showed superior efficacy over placebo in earlier trials for migraine treatment. This advances Biohaven's portfolio aimed at neurological disorders.
Biohaven Pharmaceutical (NYSE: BHVN) reported a net loss of $180.9 million for Q2 2020, equating to $3.08 per share, a slight improvement from the previous year's loss of $211.1 million. The company achieved net product revenues of $9.7 million from NURTEC ODT, showing strong prescription growth driven by effective virtual engagement strategies during the COVID-19 pandemic. Biohaven secured a $500 million non-dilutive credit facility and announced a $450 million funding agreement with Royalty Pharma to support its pipeline developments while maintaining a robust cash position of $263.9 million.
FAQ
What is the current stock price of Biohaven (BHVN)?
What is the market cap of Biohaven (BHVN)?
